PRESENCE OF A SPECIFIC ANTIESTROGEN BINDING-SITE ON HUMAN FOLLICULAR THYROID-CARCINOMA CELL-LINE (UCLA RO 82 W-1) - INHIBITION BY AN ENDOGENOUS LIGAND PRESENT IN HUMAN SERUM

被引:16
作者
GROSS, C
YU, M
VANHERLE, AJ
GIULIANO, AE
JUILLARD, GJF
机构
[1] UNIV CALIF LOS ANGELES, SCH MED, DIV ENDOCRINOL, LOS ANGELES, CA 90024 USA
[2] UNIV CALIF LOS ANGELES, SCH MED, DEPT RADIAT ONCOL, LOS ANGELES, CA 90024 USA
[3] JOHN WAYNE CANC INST, DIV SURG ONCOL, SANTA MONICA, CA 90404 USA
关键词
D O I
10.1210/jc.77.5.1361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A receptor for antiestrogens, distinct from the estrogen receptor, has been identified in several tissues including the MCF-7 breast cancer cell line. Estrogen receptors have also been found in normal and pathological thyroid tissue homogenates. We demonstrate the presence of an antiestrogen binding site (AEBS) on a pure human follicular thyroid carcinoma cell line (UCLA RO 82 W-1) using a H-3-tamoxifen (H-3-TAM) binding assay. The binding of H-3-TAM to the AEBS was determined after preincubation (30 min) of the cells with excess 17 beta-estradiol (2 mu mol/L). Specific and saturable binding of H-3-TAM to the cells was observed. Displacement of the tracer from its binding site was dose dependent. Scatchard analysis revealed a dissociation constant (K-d) of 73 nmol/L, indicating a binding site with moderate affinity and capacity (72 pmol/l0(6) cells). Using this assay we were also able to demonstrate the presence of an endogenous ligand for the AEBS in ethanol extracts of human serum. Cell growth and H-3-thymidine incorporation by the follicular thyroid carcinoma cells were inhibited when the cells were exposed to TAM (1.5 mu mol/L). In conclusion, TAM is able to bind to a specific receptor on this follicular thyroid carcinoma cell line, and a natural circulating ligand present in ethanol extracts of human serum interferes with its binding.
引用
收藏
页码:1361 / 1366
页数:6
相关论文
共 44 条
[1]  
BASELT RC, 1980, ANAL PROCEDURES THER, P298
[2]   TAMOXIFEN, SERUM-LIPOPROTEINS AND CARDIOVASCULAR RISK [J].
BRUNING, PF ;
BONFRER, JMG ;
HART, AAM ;
DEJONGBAKKER, M ;
LINDERS, D ;
VANLOON, J ;
NOOYEN, WJ .
BRITISH JOURNAL OF CANCER, 1988, 58 (04) :497-499
[3]   ESTROGEN-RECEPTOR IN NORMAL AND NEOPLASTIC HUMAN THYROID-TISSUE [J].
CHAUDHURI, PK ;
PRINZ, R .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1989, 10 (05) :322-326
[4]   AN ENDOGENOUS LIGAND FOR THE TRIPHENYLETHYLENE ANTI-ESTROGEN BINDING-SITE [J].
CLARK, JH ;
WINNEKER, RC ;
GUTHRIE, SC ;
MARKAVERICH, BM .
ENDOCRINOLOGY, 1983, 113 (03) :1167-1169
[5]   ESTROGEN AND THYROID-STIMULATING HORMONE (TSH) RECEPTORS IN NEOPLASTIC AND NONNEOPLASTIC HUMAN THYROID-TISSUE [J].
CLARK, OH ;
GEREND, PL ;
DAVIS, M ;
GORETZKI, PE ;
HOFFMAN, PG .
JOURNAL OF SURGICAL RESEARCH, 1985, 38 (02) :89-96
[6]  
COEZY E, 1982, CANCER RES, V42, P317
[7]   ACTIVITY OF TAMOXIFEN AND ITS METABOLITES ON ENDOCRINE-DEPENDENT AND ENDOCRINE-INDEPENDENT BREAST-CANCER CELLS [J].
CORADINI, D ;
CAPPELLETTI, V ;
GRANATA, G ;
DIFRONZO, G .
TUMOR BIOLOGY, 1991, 12 (03) :149-158
[8]   CHARACTERIZATION OF A HUMAN FOLLICULAR THYROID-CARCINOMA CELL-LINE (UCLA-RO 82 W-1) [J].
ESTOUR, B ;
VANHERLE, AJ ;
JUILLARD, GJF ;
TOTANES, TL ;
SPARKES, RS ;
GIULIANO, AE ;
KLANDORF, H .
VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1989, 57 (03) :167-174
[9]  
FAYE JC, 1983, P NATL ACAD SCI-BIOL, V80, P3158, DOI 10.1073/pnas.80.11.3158
[10]   ANTI-ESTROGEN SPECIFIC, HIGH-AFFINITY SATURABLE BINDING-SITES IN RAT UTERINE CYTOSOL [J].
FAYE, JC ;
LASSERRE, B ;
BAYARD, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1980, 93 (04) :1225-1231